Navigation Links
EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
Date:1/3/2008

ROCKVILLE, Md., Jan. 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for its aurora kinase/angiogenesis inhibitor, ENMD-2076.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

ENMD-2076 is a novel, dual-acting, kinase inhibitor with potent activity against Aurora A and tyrosine kinases linked to promoting cancer and inflammatory diseases. ENMD-2076 acts through multiple pathways resulting in antiproliferative activity and the inhibition of angiogenesis. ENMD-2076 has demonstrated substantial, dose-dependent efficacy as a single agent in multiple xenograft models, including tumor regression in breast, colon, and leukemia models. Importantly, ENMD-2076 is an oral agent that has shown an acceptable toxicity profile in preclinical studies without cardiovascular effects.

Carolyn F. Sidor, MD, MBA, EntreMed Vice President and Chief Medical Officer commented on the IND, "Acceptance of the Investigational New Drug application for ENMD-2076 initiates the clinical program for our first compound that targets kinases. This is an exciting class of compounds with several recently approved in oncology indications. ENMD-2076 is unique in class because it not only inhibits Aurora A selectively over Aurora B, it also inhibits a number of other kinases important in the growth of tumors and, in particular, growth factor receptors critical to angiogenesis. ENMD-2076 has potent antitumor activity
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
2. EntreMed Appoints Senior Vice President of Research and Development
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...stCall/ -- Dendreon Corporation (Nasdaq: DNDN ) t...tration (FDA) provided written acknowledgement tha...ion (BLA) for PROVENGE® (sipuleucel-T) is a c...tion Drug User Fee Act (PDUFA) date of May 1, 2010...ded BLA. Dendreon is seeking licensure for PROVEN...
(Date:11/20/2009)...ently announced that a free webinar, “Roller...rticle Characterization”, will be presented ...tion of in situ particle characterization is demon...ies of roller compaction runs while varying raw ma... , (PRWEB) November 20, 2...
(Date:11/19/2009)...tCall/ -- Omeros Corporation (Nasdaq: OMER ) toda...ird quarter ended September 30, 2009. For the thre... a net loss of $3.9 million, or $1.34 per share, a... per share, for the same period in 2008. For the n...eported a net loss of $15.5 million, or $5.29 per ...
(Date:11/19/2009)...e-FirstCall/ -- Spherix Incorporated (Nasdaq: SPE...erapy, and a provider of technical and regulatory ...logy and pharmaceutical companies, today announced...olders. ,, At the meeting, shareholders of Sphe...owing members to the Board of Directors: ,, Do...
Breaking Biology Technology:Dendreon Receives FDA Acknowledgement of Complete Response 2Dendreon Receives FDA Acknowledgement of Complete Response 3Roller Compaction Process Optimization Using At-Line Particle Characterization 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4
...Inc. (Nasdaq: CVTX ) announced today that it has ... Medicines Agency (EMEA) for ranolazine for,the tr...European Union (EU),member states. This approval f...for Medicinal Products for Human Use (CHMP) on Apr...urope as add-on therapy for the,symptomatic treatm...
... in Treatment of Heart Failure ...y 10 Bioheart, Inc.,(Nasdaq: BHRT ), a company c...logics that help monitor, diagnose and treat heart...ced it has secured worldwide,non-exclusive distrib...nitor, an interactive and simple-to-use at-home in...
...l/ -- Yongye Biotechnology,International, Inc. ("Y...),a leading distributor of plant and animal nutrie... it has engaged MSPC Certified Public,Accountants ...ditor., The Company has engaged MSPC Certified Pu...ve as the Company,s independent auditor effective,...
Other Biology Technology:CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina 2CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina 3Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients 2Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients 3Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients 4Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients 5Yongye Biotechnology International, Inc. Appoints New Independent Auditor 2
(Date:11/20/2009)...esearchers are invited to contribute their abstrac... WCO ECCEO10), the largest global meeting devoted... research and patient care. The Congress will be h...inning today, abstracts can be submitted online at...on deadline is February 4, 2010. , IOF and ESCEO...
(Date:11/20/2009)... , Toxic dust: Toxins in coal-tar-based sealcoa...ted house dust, according to a USGS study. PAHs ...ecules found in oil, coal and tar deposits, and ca...Hs are often found in house dust; however, the spe...ed. Researchers found that dust from indoor areas ...
(Date:11/20/2009)...urplus biomass from the production of flax shives,...flowered plant related to those which engulf field...is has been suggested by two studies carried out b...he journal Renewable and Sustainable Energy Revie...ntal point of view, the production of bioethanol f...
Breaking Biology News(10 mins):Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 3From toxic dust and algae to ill winds from Africa 2From toxic dust and algae to ill winds from Africa 3From toxic dust and algae to ill winds from Africa 4From toxic dust and algae to ill winds from Africa 5Flax and yellow flowers can produce bioethanol 2Wounded Warrior Project 28WWP 29 Seeks to Provide Mind Body and Spirit Healing for Combat Stress 50652 1Wounded Warrior Project 28WWP 29 Seeks to Provide Mind Body and Spirit Healing for Combat Stress 50652 2Pennsylvania DEP Lehigh Valley Berks County Air Quality Partnership Urge Public Transit Use 50648 1Pennsylvania DEP Lehigh Valley Berks County Air Quality Partnership Urge Public Transit Use 50648 2Extreme Heat Causes Major Health Problems for Older Adults 50644 1Extreme Heat Causes Major Health Problems for Older Adults 50644 2
...of photosynthesizing microbes in prehistoric rocks...pplied innovative techniques to previously unexami...on the "Slushball Earth" side of a decades-long sc...t. 29 Science Express. The lead author is Alison O...C College of Letters, Arts and Sciences. , Geologi...
...he longstanding challenges in the synthesis of pha...continuous regeneration of molecules called cofact...and environmentally friendly biocatalytic processe...y of Illinois at Urbana-Champaign and the Universi...d a microreactor that efficiently regenerates cofa...
...oming paper in the international, open-access jour...n yet between a newly identified virus and the ped.... Following their recent description of the corona...uggest this is one of the most frequently detected...infections (LRTIs). These infections are estimated...
Other Biology News:Study casts doubt on 'Snowball Earth' theory 2Microreactor efficiently regenerates cofactors for biocatalysis 2A novel virus for croup 2
...nes ,High Quality, Functionally-Validated, Ion Cha... having a critical role in nerve and muscle functi...NS and the heart. Drugs that modulate ion channels... as neuropathic pain, cardiac arrhythmia, hyperten...
Mouse Anti-Human TTC3 Monoclonal Antibody, Unconjugated, Clone 2D10 from Abnova Corporation
Mouse Anti-Human DENR Monoclonal Antibody, Unconjugated, Clone 1H3 from Abnova Corporation
Mouse Anti-Human CRKRS Monoclonal Antibody, Unconjugated, Clone 3C1 from Abnova Corporation
Biology Products: